¹²³I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy

TY - JOUR

T1 - 123I‐MIBG imaging for detection of anthracycline‐induced cardiomyopathy

AU - Laursen, Adam Høgsbro

AU - Thune, Jens Jakob

AU - Hutchings, Martin

AU - Hasbak, Philip

AU - Kjaer, Andreas

AU - Elming, Marie B

AU - Ripa, Rasmus S

N1 - © 2017 Scandinavian Society of Clinical Physiology and Nuclear Medicine. Published by John Wiley & Sons Ltd.

PY - 2018/3

Y1 - 2018/3

N2 - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. (123) I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of (123) I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of (123) I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.

AB - Due to improvements in early detection and treatment of malignant disease, the population of cancer survivors is constantly expanding. Cancer survivors are faced with chemotherapy-related long-term side effects, including irreversible cardiac injury with risk of heart failure (HF). Numerous antineoplastic regimens are associated with risk of cardiac side effects, but anthracyclines in particular carry a severe risk of cardiotoxicity. Currently, serial echocardiographic evaluation of resting left ventricular ejection fraction (LVEF) is the gold standard for monitoring anthracycline-induced cardiac side effects from chemotherapy. LVEF measurements are, however, limited by their low sensitivity. A normal LVEF does not exclude cardiotoxicity and declines in LVEF are usually not observed before the occurrence of irreversible cardiomyopathy. Hence, a clinically applicable high-sensitivity diagnostic tool for early detection of chemotherapy-related cardiotoxicity is still lacking and alternative non-invasive imaging modalities are therefore being investigated. (123) I-MIBG is a noradrenaline (NA) analogue used for evaluation of cardiac adrenergic function, including assessment of HF prognosis and evaluation of HF treatment response. However, the role of (123) I-MIBG for monitoring chemotherapy-related cardiotoxicity is still unclear. Here, we review the value of (123) I-MIBG imaging for early detection and prevention of anthracycline-induced cardiomyopathy.

KW - Journal Article

KW - Review

U2 - 10.1111/cpf.12419

DO - 10.1111/cpf.12419

M3 - Review

C2 - 28251781

SN - 1475-0961

VL - 38

SP - 176

EP - 185

JO - Clinical Physiology and Functional Imaging

JF - Clinical Physiology and Functional Imaging

IS - 2

ER -